Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus [2]

Annals of the Rheumatic Diseases

Volumn 64, Issue 10, 2005, Pages 1517-1519

  Lorenz, H M ^a   Grunke, M ^b   Wendler, J ^b   Heinzel, P A ^c   Kalden, J R ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Euro Nippon Kayaku GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GUANIDINE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANEMIA; BACTERIAL INFECTION; BRONCHITIS; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE REGIMEN; HERPES ZOSTER; HUMAN; LETTER; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL EXAMINATION; PARAGEUSIA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; UROGENITAL TRACT INFECTION; CHEMICALLY INDUCED DISORDER; FEMALE; MIDDLE AGED; OPPORTUNISTIC INFECTION;

ADULT; FEMALE; GUANIDINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MIDDLE AGED; OPPORTUNISTIC INFECTIONS;

EID: 27744574728     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.035329     Document Type: Letter

References (8)

1. Nemoto K, Mae T, Saiga K, Matsuura E, Koike T. Autoimmune-prone (NZW × BXSB)F1 (W/BF1) mice escape severe thrombocytopenia after treatment with deoxyspergualin, an immunosuppressant. Br J Haematol 1995;91:691-6.
2. Amemiya H, Koyama I, Kyo M, Kozaki K, Yuzawa K, Sakamoto K, et al. Outline and long-term prognosis in 15-deoxyspergualin-treated cases. Japan Collaborative Transplant Study Group of NKT-01. Transplant Proc 1996;28:1156-8.
3. Hotta O, Furuta T, Chiba S, Yusa N, Taguma Y. Immunosuppressive effect of deoxyspergualin in proliferative glomerulonephritis. Am J Kidney Dis 1999;34:894-901.
4. Birck R, Warnatz K, Lorenz H-M, Choi M, Haubitz M, Grunke M, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7.
5. Gores PF. Deoxyspergualin: clinical experience. Transplant Proc 1996;28:871-2.
6. Ramos EL, Nadler SG, Grasela DM, Kelley SL. Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant Proc 1996;28:873-5.
7. Nemoto K, Ogino M, Ohinata A, Hirashima K. Unique action of an immunosuppressive agent, deoxyspergualin, on hematopoiesis in mice. Exp Hematol 1997;25:1339-46.
8. Seki T, Tanda K, Chikaraishi T, Takeuchi I, Kanagawa K, Togashi M, et al. Addition of deoxyspergualin to standard triple immunosuppressive regimen in kidney transplantation. Transplant Proc 1996;28:1352-3.